Significance of allelic variants of interleukin-28B gene in chronic hepatitis C


Cite item

Full Text

Abstract

Chronic hepatitis C remains one of the most urgent problems of today's medicine. The review unravels the current view of the role of a single nucleotide polymorphism of the interleukin-28B (IL-28B) gene in different aspects of hepatitis C virus infection. Major attention is paid to the discussion of the value of the allelic variants of IL-28B during standard double and current triple antiviral therapy for chronic hepatitis C. Furthermore, the paper covers the biological role of interferon-λ, a product of IL-28A, B, and IL-29 gene expression, other associations of the allelic variants of the IL-28B gene with different clinical signs, as well as the possibilities of practical use of this genetic marker in chronic hepatitis C today and futures prospects.

Full Text

Значение аллельных вариантов гена интерлейкина-28В при хроническом гепатите С. - Аннотация. Хронический гепатит С остается одной из наиболее актуальных проблем сегодняшней медицины. В обзоре раскрывается современный взгляд на роль полиморфизма единичных нуклеотидов гена интерлейкина-28В (ИЛ-28В) при различных аспектах инфекции вирусом гепатита С. Основное внимание уделено обсуждению значения аллельных вариантов ИЛ-28В при проведении стандартной двухкомпонентной и современной трехкомпонентной противовирусной терапии хронического гепатита С. Кроме того, освещаются биологическая роль интерферона-λ - продукта экспрессии генов ИЛ-28А, В и ИЛ-29, другие ассоциации аллельных вариантов гена ИЛ-28В с различными клиническими признаками, возможности практического применения данного генетического маркера при хроническом гепатите С в настоящее время и перспективы на будущее.
×

References

  1. Sheppard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
  2. Thomas D.L., Seeff L.B. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
  3. Бобров А.Н., Белякин С.А., Плюснин С.В. Этиологическая структура циррозов печени по результатам пятнадцатилетнего наблюдения. Вестн Рос воен-мед академ 2011; 1: 76-80.
  4. Мироджов Г.К., Авезов С.А., Тухтаева Н.С. и др. Продолжительность жизни больных и прогностическое значение проявлений и осложнений цирроза печени. Рос журн гастроэнтерол, гепатол, колопроктол 2010; 5: 27-32.
  5. Бурневич Э.З., Никулкина Е.Н. Цирроз печени в исходе хронического гепатита С: трудности противовирусной терапии. Фарматека 2011; 12: 46-52.
  6. Кузнецов С.Д., Макашова В.В., Шабалина С.В. Противовирусная терапия хронического гепатита С. Инфекц бол 2010; 8: 50-54.
  7. Нечаева Л.С., Малов И.В. Противовирусная терапия хронического вирусного гепатита С на современном этапе. Сиб мед журн 2005; 57: 4-11.
  8. Yu M.L., Lin S.M., Chuang W.L. et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-994.
  9. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
  10. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  11. Hadziyannis S.J., Sette H.Jr., Morgan T.R. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  12. Jacobson I.M., Brown R.S.Jr., Freilich B. et al. Peginterferon alfa-2b and weightbased or flat dosed ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-981.
  13. Бакулин И.Г. Противовирусная терапия хронического гепатита С: индивидуальный подход через призму вирусологического ответа. Best clinical practice. Рус. Изд. 2010: 6-12.
  14. Богословская Е.В., Шипулин Г.А., Родионова Е.Н. и др. Оценка эффективности противовирусной терапии хронического гепатита С в максимально ранние сроки. Рос журн гастроэнтерол, гепатол, колопроктол 2007; 2: 35-39.
  15. Сюткин В.Е., Иваников И.О. Оптимизация противовирусной терапии больных хроническим гепатитом С на основании изучения виремии в процессе лечения. Кремлевская медицина. Клин вестн 2007; 2: 60-61.
  16. Zeuzem S., Buti M., Ferenci P. et al. Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
  17. Jensen D.M., Morgan T.R., Marcellin P. et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-960.
  18. Lagging M., Langeland N., Pedersen C. et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-1845.
  19. Mangia A., Santoro R., Minerva N. et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
  20. Nakagawa M., Sakamoto N., Ueyama M. et al. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 2010; 45: 656-665.
  21. Murayama M., Katano Y., Nakano I. et al. A mutation in the interferon sensitivity determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b. J Med Virol 2007; 79: 35-40.
  22. Akuta N., Suzuki F., Hirakawa M. et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-458.
  23. Kitamura S., Tsuge M., Hatakeyama T. et al. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir Ther 2010; 15: 1087-1097.
  24. Poynard T., McHutchison J., Goodman Z. et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31: 211-218.
  25. Селиверстова Т.Р., Труфанова Ю.М., Морозов С.В., Исаков В.А. Показатели состава тела как факторы прогноза эффективности противовирусной терапии при хроническом гепатите С. Экспер и клин гастроэнтерол 2011; 1: 54-58.
  26. Charlton M., Pockros P.J., Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-1186.
  27. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12: 6756-6765.
  28. McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
  29. Roffi L., Colloredo G., Pioltelli P. et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008; 13: 663-673.
  30. Villa E., Karampatou A., Camma C. et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterol 2011; 140: 818-829.
  31. Muir A.J., Bornstein J.D., Killenberg P.G. Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
  32. Missiha S., Heathcote J., Arenovich T. et al. Impact of Asian race on response to combination therapy with pegylated interferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-2188.
  33. Conjeevaram H.S., Fried M.W., Jeffers L.J. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
  34. Buch S., Schafmayer C., Volzke H. et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007; 39: 995-999.
  35. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  36. Tanaka Y., Nishida N., Sugiyama M. et al. Genome-wide association of IL28B with response to PEGylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
  37. Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
  38. Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
  39. Козина А. Н., Абрамов Д. Д., Климова Е. А. и др. Возможности персонифицированного подхода к лечению гепатита С на основании разработанных генетических тестов определения варианта полиморфизма гена ИЛ. Леч врач 2011; 10: 15-17.
  40. Мицура В.М., Воропаев Е.В., Воропаева А.В. Значение определения генотипов вируса гепатита С и вирусной нагрузки у больных хроническим гепатитом С. Мед-биол пробл жизнедеят 2009; 2: 94-98.
  41. Николаева Л.И., Самохвалов Е.И., Альховский С.В. и др. Генетический полиморфизм и эффективность противовирусной терапии при хроническом вирусном гепатите С. Вестн Рос ун-та дружбы народов. Серия "Медицина" 2012; 2: 81-88.
  42. Coto-Llerena M., Perez-Del-Pulgar S., Crespo G. et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.
  43. Fukuhara T., Taketomi A., Motomura T. et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
  44. Motomura T., Taketomi A., Fukuhara T. et al. The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Am J Transplant 2011; 11: 1325-1329.
  45. Rallon N.I., Naggie S., Benito J.M. et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C viruscoinfected patients. AIDS 2010; 24: F23-F29.
  46. Aparicio E., Parera M., Franco S. et al. IL28B SNP rs8099917 is strongly associated with PEGylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5: e13771.
  47. Pineda J.A., Caruz A., Rivero A. et al. Prediction of response to PEGylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51: 788-795.
  48. Medrano J., Neukam K., Rallon N. et al. Modeling the probability of sustained virological response to therapy with PEGylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51: 1209-1216.
  49. Grebely J., Petoumenos K., Hellard M. et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
  50. Nattermann J., Vogel M., Nischalke H.D. et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIVpositive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203: 595-601.
  51. Chayama K., Hayes C.N., Abe H. et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
  52. Akuta N., Suzuki F., Hirakawa M. et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
  53. Akuta N., Suzuki F., Hirakawa M. et al. Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment. Intervirology 2012; 55: 231-241.
  54. Jacobson I.M., McHutchison J.G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  55. Jacobson I.M., Catlett I., Marcellin P. et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54 (Suppl.): S542-S543.
  56. Bronowicki J.P., Hezode C., Bengtsson L. et al. 100% SVR in IL28B CC Patients Treated with 12 Weeks of Telaprevir, Peginterferon and Ribavirin in the PROVE2 Trial. J Hepatol 2012; 55 (Suppl.): A. 1094.
  57. Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  58. Pol S., Aerssens J., Zeuzem S. et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54 (Suppl.): S6-S7.
  59. Poordad F., McCone J.Jr., Bacon B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  60. Bacon B.R., Gordon S.C., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  61. Poordad F., Bronowicki J.P., Gordon S.C. et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with bocepreivr combination therapy. J Hepatol 2011; 54 (Suppl.): S6.
  62. Li J.H., Lao X.Q., Tillmann H.L. et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-1911.
  63. Montes-Cano M.A., Garcıa-Lozano J.R., Abad-Molina C. et al. Interleukin-28B genetic variants and hepatitis virus infection by differentviral genotypes. Hepatology 2010; 52: 33-37.
  64. McCarthy J.J., Li J.H., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to PEGylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
  65. Akuta N., Suzuki F., Hirakawa M. et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with PEGinterferon and ribavirin. Hepatology 2010; 52: 421-429.
  66. Tillmann H.L., Thompson A.J., Patel K. et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592.
  67. Abe H., Ochi H., Maekawa T. et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-443.
  68. Kurosaki M., Tanaka Y., Nishida N. et al. Pre-treatment prediction of response to PEGylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-448.
  69. Marabita F., Aghemo A., De Nicola S. et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-1134.
  70. McCarthy J., Li J., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
  71. Montes-Cano M.A., Garcia-Lozano J.R., Abad-Molina C. et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
  72. Sarrazin C., Susser S., Doehring A. et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
  73. Lindh M., Lagging M., Norkrans G., Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010; 139: 1794-1796.
  74. Statermayer A.F., Stauber R., Hofer H. et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
  75. Mangia A., Thompson A.J., Santoro R. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
  76. Clark P.J., Thompson A.J., McHutchison J.G. IL28B genomicbased treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106: 38-45.
  77. Neumann A.U., Bibert S., Haagmans B. IL28B polymorphism is significantly correlated with IFN anti-viral effectiveness already on first day of pegylated interferon-a and ribavirin therapy of chronic HCV infection. J Hepatol 2010; 52 (Suppl. 1): S. 468.
  78. Thompson A.J., Muir A.J., Sulkowski M.S. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
  79. Rallon N.I., Soriano V., Naggie S. et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C viruscoinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25: 1025-1033.
  80. Lampertico P., Vigano M., Cheroni C. et al. Genetic variation in IL28B polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated with interferon alfa wabstractx. Hepatology 2010; 52: 442A.
  81. Martin M.P., Qi Y., Goedert J.J. et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749-1753.
  82. Kamatani Y., Wattanapokayakit S., Ochi H. et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-595.
  83. Fellay J., Shianna K.V., Ge D. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-947.
  84. Li M., Liu X., Zhou Y., Su S.B. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
  85. Fox B.A., Sheppard P.O., O'Hara P.J. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 2009; 4: e4933.
  86. Marcello T., Grakoui A., Barba-Spaeth G. et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
  87. Witte K., Witte E., Sabat R., Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21: 237-251.
  88. Urban T.J., Thompson A.J., Bradrick S.S. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
  89. Honda M., Sakai A., Yamashita T. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
  90. Abe H., Hayes N., Ochi H. et al. IL28B variation affects expression of interferon stimulated genes and effect of PEG-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094-1101.
  91. Chen L., Borozan I., Feld J. et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-1444.
  92. Feld J.J., Nanda S., Huang Y. et al. Hepatic gene expression during treatment with PEGinterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563.
  93. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039.
  94. Dill M.T., Duong F.H., Vogt J.E. et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
  95. Patterson J.L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1132-1146.
  96. Bodenheimer H.C., Lindsay K.L., Davis G.L. et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-477.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies